Fibroblast growth factor 23 (FGF23) which is produced in bone participates LY-411575 in the maintenance of phosphate metabolism and can serve as a LY-411575 biomarker for cardiovascular adverse outcomes in patients with chronic kidney and end-stage renal disease. of FGF23…